S&P 500   5,039.81 (-0.23%)
DOW   37,839.36 (+0.11%)
QQQ   426.83 (-0.99%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,039.81 (-0.23%)
DOW   37,839.36 (+0.11%)
QQQ   426.83 (-0.99%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,039.81 (-0.23%)
DOW   37,839.36 (+0.11%)
QQQ   426.83 (-0.99%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
S&P 500   5,039.81 (-0.23%)
DOW   37,839.36 (+0.11%)
QQQ   426.83 (-0.99%)
AAPL   169.38 (-1.92%)
MSFT   414.58 (+0.23%)
META   499.76 (-0.09%)
GOOGL   154.40 (-0.30%)
AMZN   183.32 (-0.16%)
TSLA   157.11 (-2.71%)
NVDA   874.15 (+1.64%)
AMD   163.46 (+1.96%)
NIO   3.81 (-2.06%)
BABA   69.61 (-1.43%)
T   16.09 (-0.92%)
F   12.09 (-1.14%)
MU   121.77 (+0.33%)
GE   156.76 (+1.99%)
CGC   6.70 (-4.01%)
DIS   113.88 (+0.82%)
AMC   2.72 (+10.12%)
PFE   25.69 (-0.85%)
PYPL   63.43 (-0.13%)
XOM   118.69 (-0.83%)
NASDAQ:ACHL

Achilles Therapeutics (ACHL) Stock Price, News & Analysis

$0.81
+0.01 (+1.22%)
(As of 01:22 PM ET)
Today's Range
$0.79
$0.83
50-Day Range
$0.80
$1.57
52-Week Range
$0.74
$1.76
Volume
160,128 shs
Average Volume
700,443 shs
Market Capitalization
$32.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Achilles Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
391.6% Upside
$4.00 Price Target
Short Interest
Healthy
0.19% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.34) to ($1.33) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.13 out of 5 stars

Medical Sector

542nd out of 913 stocks

Biological Products, Except Diagnostic Industry

85th out of 147 stocks

ACHL stock logo

About Achilles Therapeutics Stock (NASDAQ:ACHL)

Achilles Therapeutics Plc, a clinical stage immuno-oncology biopharmaceutical company, develops precision T cell therapies to treat various solid tumors. The company's lead product candidates include CHIRON, which is in Phase I/IIa clinical trial for use in the treatment of advanced non-small cell lung cancer; and THETIS, a product candidate in Phase I/IIa clinical trial for use in the treatment of metastatic or recurrent melanoma. The company was formerly known as Achilles TX Limited and changed its name to Achilles Therapeutics Plc in February 2021. Achilles Therapeutics Plc was founded in 2016 and is headquartered in London, the United Kingdom.

ACHL Stock Price History

ACHL Stock News Headlines

Warning: Biden’s revenge against Trump voters?
Is THIS Joe Biden’s planned revenge against Trump? Bumbling Biden will lose in November.
Achilles Therapeutics (NASDAQ:ACHL) Price Target Cut to $6.00
ACHL Stock Earnings: Achilles Therapeutics Misses EPS for Q4 2023
Warning: Biden’s revenge against Trump voters?
Is THIS Joe Biden’s planned revenge against Trump? Bumbling Biden will lose in November.
Achilles Therapeutics PLC ADR
Achilles Therapeutics PLC ADR (ACHL)
ACHL Achilles Therapeutics plc
See More Headlines
Receive ACHL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achilles Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/04/2023
Today
4/17/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:ACHL
Fax
N/A
Employees
234
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$6.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+398.6%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

Net Income
$-69,670,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$3.49 per share

Miscellaneous

Free Float
37,734,000
Market Cap
$31.99 million
Optionable
Not Optionable
Beta
1.09
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Key Executives

  • Dr. Iraj Ali Ph.D. (Age 49)
    CEO & Director
  • Dr. Karl Stuart Peggs M.D. (Age 57)
    Founder & Chief Medical Officer
  • Dr. Mark William Lowdell BSc (Age 61)
    FRCPath, MICR, MSc, Ph.D., Founder
  • Dr. Charles Swanton FMEDSCI (Age 51)
    M.D., Ph.D., Founder
  • Dr. Sergio A. Quezada Ph.D. (Age 48)
    Founder & Chief Scientific Officer
  • Mr. Robert Coutts (Age 40)
    Chief Financial Officer
  • Mr. Lee M. Stern
    Vice President of Investor Relations & External Communications
  • Mr. Daniel Carey Cazel Hood
    General Counsel & Company Secretary
  • Julia Wilson
    Head of Communications
  • Mr. Tariq Ahmed
    Executive Vice President of People

ACHL Stock Analysis - Frequently Asked Questions

Should I buy or sell Achilles Therapeutics stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Achilles Therapeutics in the last twelve months. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ACHL shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACHL, but not buy additional shares or sell existing shares.
View ACHL analyst ratings
or view top-rated stocks.

What is Achilles Therapeutics' stock price target for 2024?

3 analysts have issued 1-year target prices for Achilles Therapeutics' stock. Their ACHL share price targets range from $2.00 to $6.00. On average, they predict the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 391.6% from the stock's current price.
View analysts price targets for ACHL
or view top-rated stocks among Wall Street analysts.

How have ACHL shares performed in 2024?

Achilles Therapeutics' stock was trading at $0.8890 on January 1st, 2024. Since then, ACHL stock has decreased by 8.5% and is now trading at $0.8136.
View the best growth stocks for 2024 here
.

Are investors shorting Achilles Therapeutics?

Achilles Therapeutics saw a increase in short interest in March. As of March 31st, there was short interest totaling 74,800 shares, an increase of 8.6% from the March 15th total of 68,900 shares. Based on an average daily trading volume, of 768,800 shares, the days-to-cover ratio is currently 0.1 days. Approximately 0.2% of the company's stock are sold short.
View Achilles Therapeutics' Short Interest
.

When is Achilles Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our ACHL earnings forecast
.

How were Achilles Therapeutics' earnings last quarter?

Achilles Therapeutics plc (NASDAQ:ACHL) announced its quarterly earnings data on Friday, August, 4th. The company reported ($0.42) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by $0.02.

When did Achilles Therapeutics IPO?

Achilles Therapeutics (ACHL) raised $176 million in an IPO on Wednesday, March 31st 2021. The company issued 9,800,000 shares at $17.00-$19.00 per share. JPMorgan, BofA Securities, Piper Sandler, Chardan, Oppenheimer & Co. and Kempen & Co. acted as the underwriters for the IPO.

How do I buy shares of Achilles Therapeutics?

Shares of ACHL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ACHL) was last updated on 4/17/2024 by MarketBeat.com Staff

From Our Partners